Breast cancer risk associated with being treated for infertility: results from the French E3N cohort study

Gauthier, Émilien; Paolettí, Xavier; Clavel-Chapelon, F.

doi:10.1093/humrep/deh422

Cited by 90 publications

(72 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In general, our results indicated that treatment with fertility drugs is not related to breast cancer risk, a result that is in line with the main findings from most previous studies (11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22)). An exception, however, was the finding of a f4-fold increased risk of ductal breast cancer after use of progesterone.…”

Section: Discussionsupporting

confidence: 92%

“…Results, thus far, have been contradicting, as most studies found no association between use of fertility drugs and risk of breast cancer (11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22), two studies found that fertility drugs increase the risk of breast cancer (23,24), whereas two other studies found that use of fertility drugs decrease the risk of developing breast cancer (25,26). Many of the previous studies have faced various methodologic limitations, for example, low statistical power due to a low number of breast cancer cases and inability to control for potential confounders.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Risk of Breast Cancer After Exposure to Fertility Drugs: Results from a Large Danish Cohort Study

Jensen

Sharif

Svare

et al. 2007

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

Background: Few epidemiologic studies have examined the association between fertility drugs and breast cancer risk, and results have been contradicting. Using data from the largest cohort of infertile women to date, the aim of this study was to examine the effects of fertility drugs on breast cancer risk overall and according to histologic subtypes. Method: A cohort of 54,362 women with infertility problems referred to all Danish fertility clinics between 1963 and 1998 was established. A detailed data collection, including information of type and amount of treatment, was conducted. We used case-cohort techniques to calculate rate ratios (RR) of breast cancer associated with use of five groups of fertility drugs, after adjustment for parity status. Results: Three hundred thirty-one invasive breast cancers were identified in the cohort during follow-up through 1998. Analyses within cohort showed no overall increased breast

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Introductionmentioning

confidence: 99%

Risk of Breast Cancer After Exposure to Fertility Drugs: Results from a Large Danish Cohort Study

Jensen

Sharif

Svare

et al. 2007

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

show abstract

“…According to a recent French study, infertility treatments do not increase the incidence of a breast cancer. 157 More research is needed for ovarian cancer risk, despite some reassuring results.…”

mentioning

confidence: 99%

The interface between assisted reproductive technologies and genetics: technical, social, ethical and legal issues

et al. 2006

View full text Add to dashboard Cite

“…The sample size of the study may have been too limited however to detect a significant adverse effect of gonadotropin use on breast cancer risk in BRCA1/2 carriers [13]. One study reported an association between fertility treatment and an increased risk for breast cancer in women with a positive family history for breast cancer (RR 1.4; 95% CI 1.0-1.9) [37], while others did not find fertility (treatment) and breast cancer to be associated in these women [38,39]. It is possible, yet unproven that administering gonadotropins may have led to an acceleration in growth of pre-existing, but not yet detectable, tumors in the two affected BRCA1 carriers in our cohort.…”

Section: Discussionmentioning

confidence: 99%

Hereditary breast and ovarian cancer and reproduction: an observational study on the suitability of preimplantation genetic diagnosis for both asymptomatic carriers and breast cancer survivors

Derks-Smeets

Die-Smulders

Mackens

et al. 2014

Breast Cancer Res Treat

View full text Add to dashboard Cite

PurposePreimplantation genetic diagnosis (PGD) is a reproductive option for BRCA1/2 mutation carriers wishing to avoid transmission of the predisposition for hereditary breast and ovarian cancer (HBOC) to their offspring. Embryos obtained by in vitro fertilisation (IVF/ICSI) are tested for the presence of the mutation, only BRCA-negative embryos are transferred into the uterus. The suitability and outcome of PGD for HBOC is evaluated. MethodsObservational cohort study on PGD treatments for HBOC carried out in two of WesternEurope's largest PGD centres from 2006 until 2012. Male carriers, asymptomatic female carriers, and breast cancer survivors were eligible. If available, PGD on embryos cryopreserved before chemotherapy was possible. Generic PGD-PCR tests were developed based on haplotyping, if necessary combined with mutation detection. Results 70couples underwent PGD for BRCA1/2. 42/71 carriers (59.2%) were female, six (14.3%) of whom have had breast cancer prior to PGD. In total, 145 PGD cycles were performed. 720 embryos were tested, identifying 294 (40.8%) as BRCA-negative. Of fresh IVF/PGD cycles, 23.9% resulted in a clinical pregnancy. Three cycles involved PGD on embryos cryopreserved before chemotherapy; two of these women delivered a healthy child. Overall, 38 children were liveborn. Two BRCA1 carriers were diagnosed with breast cancer shortly after PGD treatment, despite negative screening prior to PGD. ConclusionsPGD for HBOC proved to be suitable, yielding good pregnancy rates for asymptomatic carriers as well as breast cancer survivors. Because of two cases of breast cancer shortly after treatment, maternal safety of IVF(/PGD) in female carriers needs further evaluation. [2,3]. The prevalence of germline BRCA1/2 mutations is estimated at 0.1-1.0% in the general population, making HBOC one of the more prevalent autosomal dominant genetic disorders [4,5].Carriers of a BRCA1/2 mutation have a 50% risk of passing this predisposition to their offspring. There are several reproductive options to circumvent this, but only two lead to a child genetically related to both partners: prenatal diagnosis and preimplantation genetic diagnosis (PGD). Prenatal diagnosis on the one hand, involves genetic testing of a fetus for the presence of a familial BRCA1/2 mutation during pregnancy, followed by pregnancy termination in case of an unfavourable result. Although applied on a small scale, reports regarding clinical experience with prenatal diagnosis for HBOC are not available in the literature to date. Preimplantation genetic diagnosis (PGD) on the other hand, involves in vitro fertilisation (IVF) with intracytoplasmic sperm injection (ICSI), followed by genetic testing of the embryos for the presence of a familial BRCA1/2 mutation before intrauterine transfer.PGD has been successfully applied since 1990 for an expanding list of monogenic disorders and chromosomal abnormalities [6]. In 2003, the Ethics Taskforce of the European Society of Human Reproduction and Embryology stated that it is acceptable to ...

show abstract

Breast cancer risk associated with being treated for infertility: results from the French E3N cohort study

Abstract: Our study provides evidence that treatment for infertility does not influence breast cancer risk overall. An interaction with a familial history of breast cancer is possible but should be investigated further.

Cited by 90 publications

References 26 publications

Risk of Breast Cancer After Exposure to Fertility Drugs: Results from a Large Danish Cohort Study

Risk of Breast Cancer After Exposure to Fertility Drugs: Results from a Large Danish Cohort Study

The interface between assisted reproductive technologies and genetics: technical, social, ethical and legal issues

Hereditary breast and ovarian cancer and reproduction: an observational study on the suitability of preimplantation genetic diagnosis for both asymptomatic carriers and breast cancer survivors

Contact Info

Product

Resources

About